<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004920</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08983</org_study_id>
    <secondary_id>EORTC-08983</secondary_id>
    <nct_id>NCT00004920</nct_id>
  </id_info>
  <brief_title>Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura</brief_title>
  <official_title>Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. It is not yet known whether receiving cisplatin with raltitrexed is
      more effective than cisplatin alone for malignant mesothelioma.

      PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without
      raltitrexed in treating patients who have malignant mesothelioma of the pleura.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare overall survival in patients with malignant pleural mesothelioma treated with
           raltitrexed with or without cisplatin.

        -  Assess toxicity, progression free survival, and quality of life with these treatment
           regimens in these patients.

        -  Evaluate objective response and duration of response to these treatment regimens in
           patients with measurable disease.

      OUTLINE: This is a randomized, open, multicenter study. Patients are stratified according to
      performance status (0 vs 1-2) and WBC count (less than 8,300/mm3 vs 8,300/mm3 or more).
      Patients are randomized to one of two treatment arms.

        -  Arm I: Patients receive cisplatin IV over 1-2 hours on day 1.

        -  Arm II: Patients receive raltitrexed IV over 15 minutes followed by cisplatin IV over
           1-2 hours on day 1.

      Treatment continues every 3 weeks in the absence of disease progression or unacceptable
      toxicity.

      Quality of life is assessed before study, prior to each course, after the last course, and
      then every 6 weeks for 1 year.

      Patients are followed every 6 weeks until death.

      PROJECTED ACCRUAL: A total of 240 patients will be accrued for this study over 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">256</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltitrexed</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant pleural mesothelioma

          -  No CNS metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  ZUBROD, ECOG, WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Hemoglobin at least 10.0 g/dL

          -  WBC at least 4,000/mm^3

          -  Absolute neutrophil count at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.46 mg/dL

          -  Albumin at least 3.0 g/dL

          -  ALAT/ASAT less than 2.5 times upper limit of normal (ULN) (less than 5 times ULN if
             liver involvement)

        Renal:

          -  Creatinine less than 1.69 mg/dL

          -  Creatinine clearance at least 65 mL/min

        Cardiovascular:

          -  Not specified

        Pulmonary:

          -  Not specified

        Other:

          -  No other prior or concurrent malignancies within past 5 years except adequately
             treated carcinoma in situ of the cervix or basal or squamous cell carcinoma of the
             skin

          -  No prior malignant melanoma, hypernephroma or breast carcinoma

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study

          -  No uncontrolled infections

          -  No psychological, familial, sociological, or geographical condition that precludes
             study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent immunotherapy before first disease progression

        Chemotherapy:

          -  No prior systemic or intracavitary cytotoxic chemotherapy

          -  No other prior or concurrent chemotherapy before first disease progression

          -  No prior or concurrent pleurodesis with cytotoxic drugs (e.g., bleomycin)

        Endocrine therapy:

          -  No concurrent hormonal therapy except corticosteroids before first disease progression

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy to target lesion and progression observed

          -  Concurrent palliative radiotherapy to painful lesions allowed only if target lesion
             outside of irradiated field

        Surgery:

          -  Prior surgery allowed if followed by disease progression

        Other:

          -  At least 1 month since prior investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan P. Van Meerbeeck, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Rotterdam at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-Hamilton Regional Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille Hopitaux Sud</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Rohrbach</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa (Genova)</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Rotterdam Dijkzigt</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Lung Diseases Hospital</name>
      <address>
        <city>Poznan</city>
        <zip>60 569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP, Robert A. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. J Clin Oncol. 2006 Jul 1;24(19):3007-12.</citation>
    <PMID>16809726</PMID>
  </reference>
  <results_reference>
    <citation>Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP; EORTC-NCIC. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007 Dec 20;25(36):5770-6.</citation>
    <PMID>18089874</PMID>
  </results_reference>
  <results_reference>
    <citation>Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J; EORTC Lung-Cancer Group; National Cancer Institute, Canada. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006 Mar 20;24(9):1435-42. Epub 2006 Jan 30. Erratum in: J Clin Oncol. 2006 Jun 1;24(16):2601. Gaafa, Rabab [corrected to Gaafar, Rahab].</citation>
    <PMID>16446322</PMID>
  </results_reference>
  <results_reference>
    <citation>van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005 Oct 1;23(28):6881-9.</citation>
    <PMID>16192580</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Meerbeeck JP, Manegold C, Gaafar R, et al.: A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. [Abstract] J Clin Oncol 22 (Suppl 14): A-7021, 622s, 2004.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

